Inscripta, Inc. has introduced its cutting-edge biomanufacturing capabilities designed to produce sustainable and high-quality anti-aging skincare ingredients. Utilizing its innovative GenoScaler™ whole-genome engineering platform, the company aims to enhance the speed and reliability of ingredient production.
The shift from traditional plant-based sourcing to commercial biomanufacturing addresses critical industry challenges, including the environmental impact of extraction processes and the inconsistency of supply chains. Inscripta’s method also aims to reduce impurities often found in natural extracts, offering a more reliable option for cosmetic brands and consumers.
In collaboration with commercial partners, Inscripta is developing ingredients that meet the rising demand from leading skincare brands, ensuring both efficacy and quality.
Sri Kosaraju, President and CEO of Inscripta, underscored the potential of the bioeconomy across various markets. “We see tremendous opportunity for the bioeconomy to not only meet demands in personal care but also improve sustainability and supply chain stability,” Kosaraju stated. He emphasized the dual focus on creating productive strains and establishing scalable manufacturing processes.
The GenoScaler™ platform employs CRISPR technology to optimize microbial strains for biomanufacturing, with recent research achieving commercially viable productivity levels. This advancement marks a significant step forward in producing high-performing strains ready for market application.
Inscripta’s innovations promise a viable alternative to traditional ingredient sourcing, enhancing supply chain consistency, product quality, and reducing environmental impact across multiple sectors.